← Scroll for more →
Biogen Inc. (BIIB)
Biological Products, (No Diagnostic Substances)
Latest Price
$253.62
TTM P/E
109.32
Normalized P/E
23.46
TTM Div Yield
--
Fwd Div Yield
--
Book Value
128.06
P/B Ratio
1.98
Valuation metrics
adjust assumptions →EPS: $8.79
Book value / share: $124.37
Formula: √(22.5 × EPS × BVPS)
Graham Number
$156.83
38% downside
Norm. op. income: $4.6B (median of 3yr)
Tax rate: 16%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$237.25
6% downside
Base FCF: $2.1B (median of recent 5yr)
Growth: -13%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$44.88
82% downside
EPS: $8.79
Target P/E: 23×
Formula: EPS × P/E
P/E Fair Value
$202.17
20% downside
Institutional Ownership
97.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 18.22M | $3.94B | 12.35% | +5.41M | 2026-06-30 |
| BlackRock, Inc. | 15.99M | $3.45B | 10.84% | +11.1K | 2026-06-30 |
| Primecap Management Co | 15.15M | $3.27B | 10.27% | +397.0K | 2026-06-30 |
| Vanguard Capital Management LLC | 9.65M | $2.08B | 6.54% | +113.7K | 2026-06-30 |
| State Street Corp | 7.34M | $1.59B | 4.98% | +176.4K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 6.60M | $1.43B | 4.48% | +73.2K | 2026-06-30 |
| Geode Capital Management, LLC | 4.45M | $957.0M | 3.02% | +106.7K | 2026-06-30 |
| Wellington Management Group LLP | 3.12M | $673.0M | 2.11% | +155.8K | 2026-06-30 |
| Norges Bank | 2.58M | $557.0M | 1.75% | -58.8K | 2026-06-30 |
| Morgan Stanley | 2.41M | $520.0M | 1.63% | +240.3K | 2026-06-30 |